N4 Pharma Plc
N4P.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 272.9% | – | – | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -16,767.4% | -68,356.4% | – | – |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -14,542.7% | -64,977% | – | – |
| EPS Diluted | -0.003 | -0.005 | -0.006 | -0.009 |
| % Growth | 40.4% | 5.5% | 35.3% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | £0 | £0 | £0 | £0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |